Literature DB >> 20452225

Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.

Marc Lamblin1, Basel Dabbas, Russell Spingarn, Rodrigo Mendoza-Sanchez, Tian-Tian Wang, Beum-Soo An, Dao Chao Huang, Richard Kremer, John H White, James L Gleason.   

Abstract

Incorporation of zinc-binding groups into the side-chain of 1alpha,25-dihydroxyvitamin D(3) (1,25D) fully bifunctional hybrid molecules which act both as vitamin D receptor agonists and histone deacetylase inhibitors. These bifunctional hybrids display in vitro antiproliferative activity against the AT84 squamous carcinoma cell line while lacking the in vivo hypercalcemic effects of 1,25D.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452225     DOI: 10.1016/j.bmc.2010.03.078

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

Review 1.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

Review 2.  HDACs and HDAC Inhibitors in Cancer Development and Therapy.

Authors:  Yixuan Li; Edward Seto
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

3.  Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.

Authors:  Anton V Bieliauskas; Sujith V W Weerasinghe; Ahmed T Negmeldin; Mary Kay H Pflum
Journal:  Arch Pharm (Weinheim)       Date:  2016-04-09       Impact factor: 3.751

4.  A protecting group-free synthesis of (-)-hortonones A-C from the Inhoffen-Lythgoe diol.

Authors:  Hovsep Stambulyan; Thomas G Minehan
Journal:  Org Biomol Chem       Date:  2016-09-21       Impact factor: 3.876

Review 5.  Dual Inhibitors Against Topoisomerases and Histone Deacetylases.

Authors:  Young Ho Seo
Journal:  J Cancer Prev       Date:  2015-06

6.  Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer.

Authors:  Camille Barbier; Ali Mansour; Aiten Ismailova; Fatemeh Sarmadi; David A Scarlata; Manuella Bouttier; Camille Zeitouni; Catherine Wang; James L Gleason; John H White
Journal:  Sci Rep       Date:  2022-04-25       Impact factor: 4.996

7.  Molecular modeling study on tunnel behavior in different histone deacetylase isoforms.

Authors:  Sundarapandian Thangapandian; Shalini John; Yuno Lee; Venkatesh Arulalapperumal; Keun Woo Lee
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.